Loading
Life sciences · Journal article
One Health · October 10, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background. Antimicrobial resistance (AMR) is escalating in East Africa through close human-animal-environment interactions. Extended-spectrum beta-lactamases (ESBL) and carbapenemase-producing Escherichia coli are clinically critical pathogens, yet local evidence is limited. This scoping review synthesizes evidence on ESBL and carbapenemase-producing E. coli in East Africa to inform One Health AMR control strategies.Methods. Following PRISMA-ScR guidelines, PubMed and Scopus were searched, identifying 279 records published between 2015 and 2025. After removing duplicates and screening, 185 articles were assessed for eligibility; 154 studies spanning human, animal and environmental sources met the inclusion criteria. Two reviewers independently extracted epidemiological, microbiological and molecular data in Covidence, including resistance genes and transmission evidence.Results. The 154 included studies spanned 11 East African countries, led by Ethiopia (n = 55), Tanzania (n = 39) and Uganda (n = 22). Most studies (85.7%) were cross-sectional and human-focused (68.2%), with only 19 (12.3%) using a multi-sector One Health design. Overall, 21,554 E. coli isolates were recovered from 74,700 samples. ESBL prevalence was reported in 117 studies (76.0%, median 46.8%) and carbapenemase prevalence in 65 (42.2%, median 3.3%), representing heterogeneous study-level estimates. bla CTX-M predominated (89.9%), led by bla CTX-M-15 (26.1%); reported carbapenemase genes included bla NDM, bla OXA-48, bla OXA-181 and bla KPC. Whole-genome sequencing in 30 studies (19.5%) identified high-risk clones ST131, ST10, ST38 and ST410, though animal, food-chain and environmental sectors remained underrepresented.Conclusion. This review maps the current evidence on landscape for ESBL/carbapenemase- producing E. coli in East Africa, highlighting gaps in surveillance that are largely due to heterogeneity of available genomics data and limited longitudinal data within the "One Health" sectors. We recommend scaling up genomic capacity and standardized longitudinal surveillance to better understand national and regional AMR transmission and MDR E. coli infections.